Gilead Sciences Inc
NASDAQ: GILD
$83.94
+$0.04 (+0.0%)
Closing Price on September 20, 2024
GILD Articles
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Published:
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.
Published:
Gilead Sciences reported disappointing third-quarter results after the market close on Monday.
Published:
Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.
Published:
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
In a new research report, Deutsche Bank analysts suggest investors focus on sectors like technology, health care, financials and selected industrials.
Published:
A new research report from Merrill Lynch highlights 10 top catalyst-driven ideas for the fourth quarter.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
Published:
A new research report from UBS focuses on four top companies that are making great strides in treatments for patients -- and generating gigantic revenues.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Published:
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep the answers short and...
Published:
Jon OggStocks were firm yet again on Friday morning ahead of the PPI wholesale inflation report. Investors have been trying to decide where to put their money after the recent stock market volatility...
Published:
Jon OggStocks were firm on Monday morning, looking to add to the recovery bounce from Friday. Investors have now been given an opportunity to look for stocks that have pulled back that perhaps they...
Published:
In a new report from Oppenheimer, analysts combine their fundamental rating on a company of Outperform with positive earnings revisions, and then toss in a bullish technical profile for good measure.
Published: